Last reviewed · How we verify

Standard of Care - Double Oral

AOP Orphan Pharmaceuticals AG · FDA-approved active Small molecule

Standard of Care - Double Oral is a Antithrombotic combination therapy Small molecule drug developed by AOP Orphan Pharmaceuticals AG. It is currently FDA-approved for Acute coronary syndrome, Post-percutaneous coronary intervention, Atrial fibrillation with additional thrombotic risk.

This is a standard-of-care dual oral antithrombotic regimen combining two antiplatelet or anticoagulant agents to prevent thrombotic events.

This is a standard-of-care dual oral antithrombotic regimen combining two antiplatelet or anticoagulant agents to prevent thrombotic events. Used for Acute coronary syndrome, Post-percutaneous coronary intervention, Atrial fibrillation with additional thrombotic risk.

At a glance

Generic nameStandard of Care - Double Oral
SponsorAOP Orphan Pharmaceuticals AG
Drug classAntithrombotic combination therapy
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Double oral therapy typically refers to a combination of oral antiplatelet agents (such as aspirin and clopidogrel) or an oral anticoagulant with an antiplatelet agent, used to reduce the risk of thrombotic complications in cardiovascular conditions. The exact mechanism depends on the specific drug combination, but generally involves inhibition of platelet aggregation and/or coagulation cascade to prevent clot formation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Standard of Care - Double Oral

What is Standard of Care - Double Oral?

Standard of Care - Double Oral is a Antithrombotic combination therapy drug developed by AOP Orphan Pharmaceuticals AG, indicated for Acute coronary syndrome, Post-percutaneous coronary intervention, Atrial fibrillation with additional thrombotic risk.

How does Standard of Care - Double Oral work?

This is a standard-of-care dual oral antithrombotic regimen combining two antiplatelet or anticoagulant agents to prevent thrombotic events.

What is Standard of Care - Double Oral used for?

Standard of Care - Double Oral is indicated for Acute coronary syndrome, Post-percutaneous coronary intervention, Atrial fibrillation with additional thrombotic risk.

Who makes Standard of Care - Double Oral?

Standard of Care - Double Oral is developed and marketed by AOP Orphan Pharmaceuticals AG (see full AOP Orphan Pharmaceuticals AG pipeline at /company/aop-orphan-pharmaceuticals-ag).

What drug class is Standard of Care - Double Oral in?

Standard of Care - Double Oral belongs to the Antithrombotic combination therapy class. See all Antithrombotic combination therapy drugs at /class/antithrombotic-combination-therapy.

What development phase is Standard of Care - Double Oral in?

Standard of Care - Double Oral is FDA-approved (marketed).

What are the side effects of Standard of Care - Double Oral?

Common side effects of Standard of Care - Double Oral include Bleeding, Gastrointestinal hemorrhage, Dyspepsia.

Related